… majority of lung cancer cases are classified as non-small cell … IV non-small cell lung cancer
(NSCLC) [5], and the use of … to 16% of patients with stage III lung cancer [6]. Despite modest …

… response to erlotinib; however, those who had never smoked had a significant survival benefit
from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer, we …

… to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs
survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. …

… This phase II study of erlotinib in patients with HER1/EGFR-expressing non–small-cell lung
cancer previously treated with platinum-based chemotherapy evaluated tumor response, …

… advanced non-small-cell lung cancer (NSCLC) is … erlotinib has proven efficacy and tolerability
in second-line NSCLC. We designed the phase 3, placebo-controlled Sequential Tarceva …

… treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small
… these tyrosine kinase inhibitors, with a focus on erlotinib, as first-line treatment towards a …

… Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

… Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor …
with EGFR-positive non-small cell lung cancer after failure of platinum-containing chemotherapy …

… Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-small
cell lung cancer. Understanding actual use of medication is essential for optimizing treatment …

… By use of a 1-compartment model with first-order absorption, the influence of demographic
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …